Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

December 3, 2020
Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
October 22, 2020
Sirnaomics Sealed US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today... READ MORE
August 27, 2020
Sirnaomics Publishes Preclinical Study of Novel siRNA-Gemcitabine Conjugate for Advancing RNAi Therapeutics to Treat Multiple Types of Cancers Sirnaomics, Inc. , a leading biopharmaceutical company in discovery and development of RNAi therapeutics for treatment... READ MORE
August 24, 2020
RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines,... READ MORE
June 20, 2020
Sirnaomics and Precision NanoSystems Have Formed a Partnership Developing and Manufacturing Novel RNAi drug Candidates Using Precision NanoSystems’ NxGen™ Platform Sirnaomics Inc. (Sirnaomics)... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2021 by Sirnaomics, Inc.
Contact